Effect of PRP on male pattern hair loss

Assessment of autologous Platelet-Rich Plasma Injections in the Treatment of male pattern Androgenetic Alopecia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016021526563N1

Enrollment

Registered

2016-05-29

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male androgenetic alopecia. Androgenic alopecia

Interventions

injection of Platelet-Rich Plasma (PRP) 3 times in 4 weeks..

Treatment - Other

injection of Platelet-Rich Plasma (PRP) 3 times in 4 weeks.

Eligibility

Sex/Gender

Male

Age

28 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients include males with male pattern androgenetic alopecia who had acquiescence for participation in this study and their baldness is grade 3v to 5 according to Hamilton-Norwood scaling system. Exclusion criteria: using minoxidil or finasteride in the last 6 months; using any other systemic or topical supplementary drugs for hair growth stimulation in the last 6 months; using drugs that can induce hair loss (eg. Retinoids, heavy metals, antithyroids, anticonvulsants, betablockers and …); specific diseases like thyroid disease, collagen vascular disease …; positive history for any kind of cancer or skin cancer and chemotherapy; any other kind of alopecia ( scaring alopecia, alopecia areata, …); steroid therapy; coagulation disorders, acquisition of aspirin, ticlopidine or other anticoagulative drugs; dialysis patients and platelet disorders (thrombocytopenia); smoker and alcoholic persons and malnutrition; and anytime patient wants to leave the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hair loss improvement and stimulation of hair growth. Timepoint: Measurement on weeks 0, 4, 8, 12 and 3 months after last injection. Method of measurement: Average hair diameter and hair count in unit surface.	—

Secondary

Measure	Time frame
Side effects. Timepoint: At the end of treatment (3 months after last injection). Method of measurement: Effectiveness and side effects include local and systemic reactions according to patients and investigator observations.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Javad Yazdanpanah

Mashhad University of Medical Sciences

yazdanpanahmj@mums.ac.ir+98 51 3801 2493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026